The latest announcement is out from Fresenius Medical Care ( (FMS) ).
On February 24, 2025, Fresenius Medical Care announced the divestment of select laboratory assets to Quest Diagnostics, a move aimed at optimizing its portfolio and focusing on its core business of providing dialysis care. This strategic agreement will allow Quest to acquire assets from Fresenius’s Spectra Laboratories, enhancing Quest’s capabilities in dialysis-related water testing and expanding its laboratory services for end-stage kidney disease. The acquisition, expected to close in the second half of 2025, will enable Fresenius to benefit from operational efficiencies and leverage Quest’s expertise in laboratory medicine, ultimately improving patient and clinical experiences.
More about Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases, serving approximately 4.1 million patients globally who undergo regular dialysis treatment. The company operates a network of 3,732 dialysis clinics, providing treatments for around 308,000 patients worldwide, and is a leading provider of dialysis products such as machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange and the New York Stock Exchange.
YTD Price Performance: 4.24%
Average Trading Volume: 247,741
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.65B
Learn more about FMS stock on TipRanks’ Stock Analysis page.